HLS Therapeutics Inc
TSX:HLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
HMA Agro Industries Ltd
NSE:HMAAGRO
|
IN |
|
G
|
Guangdong Huiyun Titanium Industry Co Ltd
SZSE:300891
|
CN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (9.3), the stock would be worth CA$5.13 (10% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.4 | CA$4.65 |
0%
|
| 3-Year Average | 9.3 | CA$5.13 |
+10%
|
| 5-Year Average | 10.4 | CA$5.76 |
+24%
|
| Industry Average | 13.4 | CA$7.39 |
+59%
|
| Country Average | 10.2 | CA$5.61 |
+21%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
CA$183.6m
|
/ |
Jan 2026
$16.3m
|
= |
|
|
CA$183.6m
|
/ |
Dec 2026
$20.5m
|
= |
|
|
CA$183.6m
|
/ |
Dec 2027
$24.3m
|
= |
|
|
CA$183.6m
|
/ |
Dec 2028
$30.3m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
HLS Therapeutics Inc
TSX:HLS
|
145.4m CAD | 8.4 | -8.4 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
103.6B USD | 16.8 | 23.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
62.9B USD | 13.7 | 38.7 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.8B USD | 13.3 | 37.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
48.4B USD | 14.1 | 29.1 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.7B AUD | 26.4 | 35.6 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.1B CNY | 8.6 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.1B USD | 11.2 | 22.9 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 12.5 | 16.2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
63.3B HKD | 0.6 | 7.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
HLS Therapeutics Inc
Glance View
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
